Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γagonist protects against myocardial ischaemia-reperfusion injury

Cardiovascular Research

Volumn 87, Issue 3, 2010, Pages 535-544

  Ye, Yumei ^a   Hu, Zhaoyong ^b   Lin, Yu ^a   Zhang, Congfang ^a   Perez Polo, Jose R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antagomir; Apoptosis; Ischaemia reperfusion injury; MiR 29; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; MICRORNA; MICRORNA 29; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MCL 1; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTISENSE OLIGONUCLEOTIDE; BAX PROTEIN, MOUSE; CASP3 PROTEIN, RAT; CASPASE 3; MIRN29 MICRORNA, MOUSE; MIRN29 MICRORNA, RAT; MYELOID LEUKEMIA FACTOR 1; PROTEIN BCL 2; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; HEART CELL CULTURE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NICK END LABELING; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DISEASE MODEL; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; HEART MUSCLE; METABOLISM; MOUSE; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; TIME;

ANILIDES; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASPASE 3; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION PROFILING; MICE; MICRORNAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; THIAZOLIDINEDIONES; TIME FACTORS; TRANSFECTION;

EID: 77954766181     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq053     Document Type: Article

References (35)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116: 281-297.
2. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007;117:2369-2376.
3. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008;103:1072-1083.
4. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-424.
5. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116: 258-267.
6. Bauersachs J, Thum T. MicroRNAs in the broken heart. Eur J Clin Invest 2007;37: 829-833.
7. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007;13:486-491.
8. Yasuda S, Kobayashi H, Iwasa M, Kawamura I, Sumi S, Narentuoya B et al. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am J Physiol Heart Circ Physiol 2009;296:H1558-H1565.
9. Wynne AM, Mocanu MM, Yellon DM. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 2005;46:817-822.
10. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16:23-29.
11. Mott JL, Kobayashi S, Bronk SF, Gores GJ. miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-6140.
12. Zhou X, Cai S, Hong A, You Q, Yu P, Sheng N et al. Microfluidic PicoArray synthesis of oligodeoxynucleotides and simultaneous assembling of multiple DNA sequences. Nucleic Acids Res 2004;32:5409-5417.
13. Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 2001;280:H2313-H2320.
14. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-2207.
15. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, Zeng L et al. Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 2004;110:1128-1133.
16. Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol 2008;295:H2436-H2446.
17. Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF et al. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol 2006;291:H1158-H1169.
18. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003;83:1715-1721.
19. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002;16:1027-1040.
20. Ye Y, Lin Y, Perez-Polo JR, Birnbaum Y. Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone. Cardiovasc Drugs Ther 2008;22: 429-436.
21. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316: 575-579.
22. Zhao ZQ, Nakamura M, Wang NP, Velez DA, Hewan-Lowe KO, Guyton RA et al. Dynamic progression of contractile and endothelial dysfunction and infarct extension in the late phase of reperfusion. J Surg Res 2000;94:133-144.
23. Stein AB, Bolli R, Guo Y, Wang OL, Tan W, Wu WJ et al. The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis. J Mol Cell Cardiol 2007;42:1075-1085.
24. Taniguchi Y, Ooie T, Takahashi N, Shinohara T, Nakagawa M, Yonemochi H et al. Pio-glitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Diabetes 2006;55:2371-2378.
25. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-13032.
26. Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 2005;115:2128-2138.
27. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118.
28. O'Neill BT, Abel ED. Akt1 in the cardiovascular system: friend or foe? J Clin Invest 2005;115:2059-2064.
29. Ren XP, Wu J, Wang X, Sartor MA, Qian J, Jones K et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009;119:2357-2366.
30. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009;104:879-886.
31. Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res 2009;104:572-575.
32. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009;324:1710-1713.
33. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-689.
34. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
35. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y. The role of eNOS, iNOS, and NF-kappa B in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008;295:H343-H351.